Pandemic influenza A (H1N1) 2009 vaccination in children: A UK perspective

Journal of Paediatrics and Child Health

Volumn 49, Issue 3, 2013, Pages

  De Whalley, Philip C S ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

child; H1N1 subtype; influenza A virus; pandemic; vaccination

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; NEUTRALIZING ANTIBODY; TRIPLE VACCINE; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANTIBODY PRODUCTION; ANTIBODY TITER; CHILDHOOD MORTALITY; CONSULTATION; DRUG EFFICACY; DRUG MARKETING; EUROPEAN UNION; FEBRILE CONVULSION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MORBIDITY; NARCOLEPSY; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; SEROCONVERSION; SEROLOGY; UNITED KINGDOM;

CHILD; GREAT BRITAIN; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS;

EID: 84874982640     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/jpc.12037     Document Type: Review

References (32)

1. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med. 2009; 361: 680-689.
2. Chan M,. World Now at the Start of 2009 Influenza Pandemic. World Health Organization, 2009. Available from: http://www.who.int/%20mediacentre/news/ statements/2009/h1n1-pandemic-phase6-%2020090611/en/index.html [accessed 26 November 2012].
3. Chen M,. H1N1 in Post Pandemic Period. World Health Organization, 10 August 2010. Available from: http://www.who.int/mediacentre/%20news/statements/ 2010/h1n1-vpc-20100810/en/index.html [accessed 26 November 2012].
4. McLean E, Pebody RG,. Epidemiological report of pandemic (H1N1) 2009 in the UK. Health Protection Agency, 2010.
5. Green H, Pebody R,. Surveillance of influenza and other respiratory viruses in the UK: 2010-2011 report. Health Protection Agency, 2011.
6. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M,. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375: 1100-1108.
7. Sachedina N, Donaldson L,. Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. Lancet 2010; 376: 1846-1852.
8. Hanquet G, Van Damme P, Brasseur D, et al. Lessons learnt from pandemic A(H1N1) 2009 influenza vacination. Highlights of a European workshop in Brussels (22 March 2010). Vaccine 2011; 29: 370-377.
9. WHO. Influenza pandemic preparedness and response. Report by the secretariat. 20 January 2005. Report No.: EB115/44.
10. Salisbury DM,. H1N1 Influenza Vaccination Programme: Information Materials and Vaccine Schedule Information. Department of Health, 2009. Available from: http://www.dh.gov.uk/en/%20Publicationsandstatistics/ Lettersandcirculars/Dearcolleagueletters/%20DH-107665 [accessed 26 November 2012].
11. B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340: c2649.
12. A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 2011; 11: 91-101.
13. 2009 influenza vaccine after one and two doses in young children. Pediatr. Infect. Dis. J. 2011; 30: 402-407.
14. de Whalley P, Walker W, Snape MD, et al. A 1-year follow-on study from a randomised, head-to-head multicentre study of two pandemic influenza vaccines in children. Health Technol. Assess. 2011; 15: 1-128.
15. Andrews N, Waight P, Yung C-F, Miller E,. Age specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J. Infect. Dis. 2011; 203: 32-39.
16. Hardelid P, Fleming D, McMenamin J, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill. 2011; 16: pii=19763. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId= 19763 [accessed 26 November 2012].
17. Örtqvist Å, Berggren I, Insulander M, de, Jong B, Svenungsson B,. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v in Stockholm County, Sweden. Clin. Infect. Dis. 2011; 52: 1203-1211.
18. Pebody R, Hardelid P, Fleming D, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill. 2011; 16: pii=19791.
19. Kilpi T, Nohynek H,. Increased Risk of Narcolepsy Observed among Children and Adolescents Vaccinated with PandemrixR. National Institute for Health and Welfare, 2011. Available from: http://www.thl.fi/en-US/web/en/pressrelease?id= 24103 [accessed 26 November 2012].
20. Läkemedelsverket (Medical Products Agency). A registry based comparative cohort study in four Swedish counties of the risk for narcolepsy after vaccination with Pandemrix-a first and preliminary report. 28 March 2011.
21. European Medicines Agency. Questions and Answers on the Review of Pandemrix Influenza Vaccine (H1N1) (Split Virion, Inactivated, Adjuvanted) A/California/7/2009 (H1N1)v Like Strain (X-179A). European Medicines Agency, 27 July 2011. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/ %20Medicine-QA/2011/07/WC500109183.pdf [accessed 26 November 2012].
22. Bishop J,. Health Authorities Continue to Put Seasonal Flu Vaccine on Hold for Young Children. Australian Government, Department of Health and Ageing, 30 April 2010. Available from: http://www.%20health.gov.au/internet/main/ publishing.nsf/Content/%2097017E09250CF5A1CA257717007FCCF1/File/dept300410.pdf [accessed 26 November 2012].
23. Bishop J,. Seasonal Flu Vaccination for Young Children Can Be Resumed. Australian Government, Department of Health and Ageing, 30 July 2010. Available from: http://www.health.gov.au/internet/main/%20publishing.nsf/Content/ F8C473DAE9FFF923CA25777000082F2A/%20File/dept300710.pdf [accessed 26 November 2012].
24. US Food and Drug Administration. Fluzone Vaccine Safety. US Department of Health and Human Services, 2011. Available from: http://www.fda.gov/ BiologicsBloodVaccines/SafetyAvailability/%20VaccineSafety/ucm240037.htm [accessed 26 November 2012].
25. Bryan P, Seabroke S,. No increased risk of febrile convulsions after seasonal influenza immunisation in the UK. Lancet 2011; 377: 904.
26. Rizzo C, Rota M, Bella A, et al. Response to the 2009 influenza A(H1N1) pandemic in Italy. Euro Surveill. 2010; 15: pii=19744.
27. Bults M, Beaujean D, Richardus J, van, Steenbergen J, Voeten H,. Pandemic influenza A (H1N1) vaccination in The Netherlands: parental reasoning underlying child vaccination choices. Vaccine 2011; 29: 6226-6235. doi: 10.1016/j.vaccine.2011.06.075.
28. Bish A, Yardley L, Nicoll A, Michie S,. Factors associated with uptake of vaccination against pandemic influenza: a systematic review. Vaccine 2011; 29: 6472-6484. doi: 10.1016/j.vaccine.2011.06.107.
29. Poland G,. The 2009-2010 influenza pandemic: effects on pandemic and seasonal vaccine uptake and lessons learned for seasonal vaccination campaigns. Vaccine 2010; 28S: D3-13.
30. Ekiert D, Bhabha G, Elsliger M-A, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324: 246-251.
31. Ekiert D, Friesen R, Bhabha G, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333: 843-850.
32. Wrammert J, Koutsonanos D, Li G-M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011; 208: 181-193.